Abstract
Introduction: Cancer treatment planning in older adults is complex and requires careful balancing of survival, quality of life benefits, and risk of treatment-related morbidity and toxicity. As a result, treatment selection in this cohort tends to differ from that for younger patients. However, there are very few studies describing cancer treatment patterns in older cohorts. Methods: We used data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE Cancer Treatment Substudy (ACTS) to describe cancer treatment patterns in older adults. We used a multivariate logistic regression model to identify factors affecting receipt of treatment. Results: Of 1893 eligible Australian and United States (US) participants with incident cancer, 1569 (81%) received some form of cancer treatment. Non-metastatic breast cancers most frequently received treatment (98%), while haematological malignancy received the lowest rates of treatment (60%). Factors associated with not receiving treatment were older age (OR 0.94, 95% CI 0.91–0.96), residence in the US (OR 0.34, 95% CI 0.22–0.54), smoking (OR 0.57, 95% CI 0.40–0.81), and diabetes (OR 0.56, 95% CI 0.39–0.80). After adjustment for treatment patterns in sex-specific cancers, sex did not impact receipt of treatment. Conclusions: This study is one of the first describing cancer treatment patterns and factors affecting receipt of treatment across common cancer types in older adults. We found that most older adults with cancer received some form of cancer treatment, typically surgery or systemic therapy, although this varied by factors such as cancer type, age, sex, and country of residence.
All Related Versions
Funding Information
  • National Institutes of Health (P30 CA047904, U01 AG029824, U19 AG062682, 3U19 AG062682-02S1, 334047, 1127060)
  • National Health and Medical Research Council of Australia (P30 CA047904, U01 AG029824, U19 AG062682, 3U19 AG062682-02S1, 334047, 1127060)
  • Monash University (P30 CA047904, U01 AG029824, U19 AG062682, 3U19 AG062682-02S1, 334047, 1127060)
  • Victorian Cancer Agency (P30 CA047904, U01 AG029824, U19 AG062682, 3U19 AG062682-02S1, 334047, 1127060)

This publication has 48 references indexed in Scilit: